Biotech and Smart Health: Italian innovation in evidence

Please wait in 10sec ...

Four Italian startups participate in the Deloitte Officine Innovazione accelerator dedicated to innovation in the field of Biotech and Smart Health

A very important share of the innovation that will serve in the coming years to transform,for the better, european nations will certainly come from their startups. In several countries, as well as at EU level, we are gearing up concretely to encourage the growth of very young innovative companies. A virtuous and organic growth,at least in the intentions. More from “patient capital” than from venture capital. This approach will be realized in many areas, including in particular Biotech and Smart Health. And with a good contribution of Italian innovation.

Several startups started from Italy and then established themselves globally in the field of innovative technologies for the medical field. An important example is that – to quote a name – of Lima Corporate. Now there are four other startups that, under the aegis of Deloitte Officine Innovazione,try to take a similar path. Starting from the participation in the Health & BioTech Accelerator.

Since last December, a team of Deloitte Officine Innovazione and its partners in the initiative (companies, investors, realities of the scientific and medical world) has participated in 12 events in various countries and “scrutinized” one by one over 350 startups and scale-up candidates.

After a selection process, he chose six finalists who will access the acceleration program. Three operate in the field of biotechnology, three in the field of healthtech. Four are Italian.

Kither Biotech is developing new therapies for rare lung disorders. The company holds the patent for a compound for the treatment of cystic fibrosis that, according to pre-clinical data, improves the therapeutic efficacy of already known farnaci and potentially the living conditions of patients. MicroMesh is a research project of the Italian Institute of Technology for the treatment of glioblastoma multiforme. It involves the use of a biocompatible and biodegradable polymer implant that facilitates the deep permeation of drugs at the site of the tumor increasing the effectiveness of therapy. Vaxxit is a biopharmaceutical startup that develops vaccines against HIV, Herpes Simplex Virus and M. Tuberculosis, diseases indicated by the WHO among the global health priorities.

Wearable Robotics was founded in 2014 as a spinoff of the Scuola Superiore Sant’Anna in Pisa: it develops and produces different types of robotic exoskeletons for clinical and industrial applications. In particular, ALExRS, bilateral exoskeleton for the rehabilitation of the upper limbs of neurological patients, already in use in several centers in Italy and Europe. The six finalist startups will now carry out pilot projects together with the different corporate partners of the acceleration project. At the end, a DemoDay scheduled for July. During the event, the startups will present themselves to the investment community, revealing the results of the pilot projects.